Greenstone launches authorized generic voriconazole for oral suspension

Pfizer generic subsidiary introduces version of drug in 40-mg-per-milliliter strength

PEAPACK, N.J. — Greenstone has launched a version of a drug used to treat fungal infections, the company said.

Greenstone, the generics subsidiary of Pfizer, announced the introduction of voriconazole for oral suspension, an authorized generic version of Pfizer's Vfend. Authorized generics are branded drugs sold at a discount under their generic names.

Greenstone is selling the drug in the 40 mg-per-milliliter strength. Vfend had sales of about $17.1 million during the 12-month period that ended in June, according to IMS Health.

 

Login or Register to post a comment.